Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem Diabetes Care touts real-world t:slim X2 insulin pump data

September 19, 2019 By Sean Whooley

Tandem Diabetes Care - updated logoTandem Diabetes Care (NSDQ:TNDM) yesterday touted real-world data from users of the t:slim X2 insulin pump.

The data, from more than 8,000 users, was published in the medical journal Diabetes Technology & Therapeutics.

San Diego-based Tandem said the study showed a 45% relative risk reduction in hypoglycemia and a 71% relative risk reduction in hypoglycemic events, both of which exceeded reductions observed in the controlled pivotal study for Basal-IQ technology.

The t:slim X2 pump is designed to monitor glucose without fingersticks and features a touchscreen, rechargeable battery, wireless technology and USB connectivity. Tandem said the pump is 38% smaller than other insulin pumps and holds up to 300 units of insulin.

The device was established as as the first in a new category of devices called ‘Alternate Controller Enabled Infusion Pumps’ or ACE pumps in February. The t:slim X2 pump was launched in the U.S. in August 2018 and approved in Canada the following October.

“This data supports the overwhelmingly positive feedback we hear from our customers using Basal-IQ technology and the clinical improvement people often report experiencing after initiating its use,” president & CEO John Sheridan said in prepared remarks. “We continue to hear that our t:slim X2 insulin pump with Basal-IQ technology is extremely simple to learn and use, which is a core tenet across all of our products, and we believe this leads to greater customer satisfaction and improved clinical outcomes.”

Shares of TNDM were up 0.9% at $61.74 per share in midday trading today.

Filed Under: Clinical Trials, Diabetes Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • FDA approves Tandem Diabetes’ advanced hybrid closed-loop controller
  • Senate confirms Dr. Stephen Hahn to lead FDA
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
  • Medicina recalls IV Luer Slip syringes
  • Eitan Group signs service agreement with Integrated Medical Systems
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS